Advertisement

Investigational New Drugs

, Volume 17, Issue 2, pp 179–182 | Cite as

Phase II Clinical Trial of Didemnin B in Patients with Recurrent or Refractory Anaplastic Astrocytoma or Glioblastoma Multiforme (NSC 325319)

  • Abraham Mittelman
  • Hoo G. Chun
  • Carmelo Puccio
  • Nancy Coombe
  • Thomas Lansen
  • Tauseef Ahmed
Article

Abstract

The activity of didemnin B, a natural product derived from the Caribbean Tunic was assessed in 16 patients with Glioblastoma multiforme. Didemnin B was administered intravenously by a short infusion at a dose of 4.3 mg/m2 and subsequently escalated to 6.3 mg/m2. No anti-tumor activity was observed. Toxicity consisted of fatigue, weakness, stomatitis, mild blood count changes, nausea and vomiting and occasional fever. Based on these results further studies with didemnin B in patients with Glioblastoma multiforme are not recommended.

Glioblastoma multiforme didemnin B brain tumors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Walker MD, Green SB, Buyar DP et al.: Randomized comparison radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Engl J Med 303: 1323–1329, 1980Google Scholar
  2. 2.
    Greig NH, Ries LG, Yancik R, Rapoport SI: Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 82: 1721–1624, 1990Google Scholar
  3. 3.
    Kelly KA, Kirkwood JM, Kapp DS: Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treatment 11: 1–26, 1984Google Scholar
  4. 4.
    Edwards MS, Levin AV, Wilson CB: Brain tumor chemotherapy: evaluation of agents in current use for phase 2 and 3 trials. Cancer Treat Rep 64: 1179–1205, 1980Google Scholar
  5. 5.
    Cooper JS, Borok TL, Ranohoff J, Carella RJ: Malignant glioma - results of combined modality therapy. JAMA 257: 2766–2770, 1987Google Scholar
  6. 6.
    Chun HG, Davies B, Hoth D et al.: Didemnin B: the first marine compound entering clinical trials as a new agent. Ind Vol 4: 279–284, 1986Google Scholar
  7. 7.
    Dorr FA, Kuhn JG, Phillips J, Van Hoff DD: Phase I clinical and pharmacokinetics investigation of didemnin B, a cyclic depsi peptide. Eur J Cancer Clin Oncol 24: 1699–1706, 1998Google Scholar
  8. 8.
    Meng L, Sin N, Crews CM: The antiproliferative agent didemnin B incompetitively inhibits palmitoyl protein thioesterase. Biochemistry 37(29): 10488–10492, 1998Google Scholar
  9. 9.
    Crews CM, Lane WS, Schreiber SL: Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA 93(9): 4316–4319, 1996Google Scholar
  10. 10.
    Malfetano JH, Blessing JA, Holnesley HD, Look Ky, McGehee R: A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Am J Clin Oncol 19(2): 184–186, 1996Google Scholar
  11. 11.
    Goss G, Muldal A, Lohmann R, Taylor M, Lopez P, Armitage G, Steward WP: Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials group. Invest New Drugs 13(3): 257–260, 1995Google Scholar
  12. 12.
    Williamson SK, Wolf MK, Eisenberger MA, O'Rourke M, Brannon W, Crawford ED: Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Invest New Drugs 13(2): 167–170, 1995Google Scholar
  13. 13.
    Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Rosenthal J, Raber MN, Hong WK: Phase II clinical trial of didemnin B in previously treated small cell lung cancer. Invest New Drugs 12(3): 243–249, 1994Google Scholar
  14. 14.
    Weiss RB, Peterson BL, Allen SL, Browning SM, Duggan DB, Schiffer CA: A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study. Invest New Drugs 12(1): 41–43, 1994Google Scholar
  15. 15.
    Sondak VK, Kopecky KJ, Liu PY, Fletcher WS, Harvey WH, Laufman LR: Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group. Anticancer Drugs 5(2): 147–150, 1994Google Scholar
  16. 16.
    Malfetano JH, Blessing JA, Jacobs AJ: A phase II trial of didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group study. Am J Clin Oncol 16(1): 47–49, 1993Google Scholar
  17. 17.
    Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Rosenthal J, Raber MN, Hong WK: Phase II clinical trial of didemnin B in previously treated small cell lung cancer. Invest New Drugs 12(3): 243–249, 1994Google Scholar
  18. 18.
    Jones DV Jr, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL: Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs 10(3): 211–213, 1992Google Scholar
  19. 19.
    Weiss GR, Liu PY, O'sullivan J, Alberts DS, Brown TD, Neefe JR, Hutchins LF: A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol-Oncol 45(3): 303–306, 1992Google Scholar
  20. 20.
    Benvenuto JA, Newman RA, Bignami GS, Raybould TJ, Raber MN, Esparza L, Walters RS: Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Invest New Drugs 10(2): 113–117, 1992Google Scholar
  21. 21.
    Taylor SA, Goodman P, Crawford ED, Stuckey WJ, Stephens RL, Gaynor ER: Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study. Invest New Drugs 10(1): 55–56, 1992Google Scholar
  22. 22.
    Cain JM, Liu PY, Alberts DE, Gallion HH, Laufman L, O'sullivan J, Weiss G, Bickers JB: Phase II trial of didemnin B in advanced epithelial ovarian cancer. A Southwest Oncology Group study. Invest New Drugs 10(1): 23–24, 1992Google Scholar
  23. 23.
    Jacobs AJ, Blessing JA, Munoz A: A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: a Gynecologic Oncology Group study. Gynecol-Oncol 44(3): 268–270, 1992Google Scholar
  24. 24.
    Shin DM, Holoye PY, Murphy WK, Forman A, Papasozomenos SC, Hong WK, Raber M: Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose limiting. Cancer Chemother Pharmacol 29(2): 145–149, 1991Google Scholar
  25. 25.
    Stewart JA, Low JB, Roberts JD, Blow A: A phase I clinical trial of didemnin B. Cancer 68(12): 2550–2554, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Abraham Mittelman
    • 1
  • Hoo G. Chun
    • 1
  • Carmelo Puccio
    • 1
  • Nancy Coombe
    • 1
  • Thomas Lansen
    • 1
    • 2
  • Tauseef Ahmed
    • 1
  1. 1.New York Medical College, Division of Oncology/HematologyValhallaUSA
  2. 2.Neurosurgeons of New YorkWhite PlainsUSA

Personalised recommendations